戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t is hoped, will facilitate ongoing study of Achromobacter.
2 icrobiologic and clinical characteristics of Achromobacter.
3 the efficacy of three different prokaryotic (Achromobacter, Agrobacterium and Bacillus) EPSPS genes.
4             The opportunistic human pathogen Achromobacter (Alcaligenes) xylosoxidans has been recove
5             Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans have been incre
6 mucin 5B]) concentration and the presence of Achromobacter and Klebsiella.
7   Scanning electron microscopy revealed that Achromobacter and Stenotrophomonas formed a biofilm on t
8 ia were prevalent in all disease groups, and Achromobacter and Stenotrophomonas were present in one a
9 ccus aureus, Burkholderia, Stenotrophomonas, Achromobacter, and nontuberculous mycobacteria that driv
10 i O157:H7, enteropathogenic E. coli O127:H6, Achromobacter, and Sinorhizobium meliloti, where the out
11 dant microbial genera were Mycobacterium and Achromobacter at 10,000 ft; Stenotrophomonas and Achromo
12 omobacter at 10,000 ft; Stenotrophomonas and Achromobacter at 20,000 ft; Delftia and Pseudoperonospor
13 rst week and Rheinheimera, Acinetobacter and Achromobacter between day 7 and 28.
14                    Among adult patients with Achromobacter bloodstream infection, the mean age was 58
15 he clinical characteristics of patients with Achromobacter bloodstream infection, the number of diffe
16 nical characteristics of adult patients with Achromobacter bloodstream isolates.
17 ve criteria and methodology are utilized for Achromobacter by clinical laboratories and likely do not
18                                    The genus Achromobacter currently is comprised of seven species, i
19 tica (Pn) nitrous oxide reductase (N2OR) and Achromobacter cycloclastes (Ac) N2OR and its relevance t
20 ture of the pink-purple species of N2OR from Achromobacter cycloclastes (AcN2OR) isolated under aerob
21 characterized members of the Pseudomonas and Achromobacter genera.
22 udy provides guidance to clinicians treating Achromobacter infections and, it is hoped, will facilita
23 e is limited data on the clinical profile of Achromobacter infections as well as optimal antibiotic s
24 prim-sulfamethoxazole as initial therapy for Achromobacter infections.
25 linical and microbiologic characteristics of Achromobacter infections.IMPORTANCEAchromobacter is a ra
26 soluble form of WssI from P. fluorescens and Achromobacter insuavis and demonstrated acetylesterase a
27  scheme, we analyzed 107 genetically diverse Achromobacter isolates cultured from biologic specimens
28 lysis of all bloodstream and non-bloodstream Achromobacter isolates identified at three tertiary-care
29 ur study consists of a 10-year survey of all Achromobacter isolates processed by three Mayo Clinic te
30                             A total of 1,598 Achromobacter isolates, encompassing 1,545 non-bloodstre
31 ent antimicrobial susceptibility results for Achromobacter isolates.
32  investigations, to clarify the taxonomy of "Achromobacter-like" strains, and to elucidate the popula
33 se IV to the lysine-specific endoprotease of Achromobacter lyticus suggested three possible disulfide
34 served in the related beta-lytic protease of Achromobacter lyticus.
35  to species Achromobacter pulmonis A (16%) & Achromobacter mucicolens (15%), Pseudomonas citronelloli
36 ssified Bacteroidales) and LNA genera (e.g., Achromobacter, Ochrobactrum, and unclassified Anaeroline
37                                              Achromobacter piechaudii strain HLE is a betaproteobacte
38 y of enzymes were found to belong to species Achromobacter pulmonis A (16%) & Achromobacter mucicolen
39 yses of taxonomically related Bordetella and Achromobacter species also indicated the presence of an
40 lusters confirmed the seven previously named Achromobacter species and revealed 14 additional genogro
41                                              Achromobacter species are Gram-negative bacilli that pre
42           Clinical and microbiologic data on Achromobacter species are limited due to the rarity of t
43                                              Achromobacter species can cause opportunistic infections
44 oodstream infection, the number of different Achromobacter species identified, and the sources of iso
45                                              Achromobacter species possess a Vi antigen-specific depo
46 ccurately predict susceptibility results for Achromobacter species.
47 tandards Institute (CLSI) AST guidelines for Achromobacter species.
48 nderstand the mechanisms mediating AMR among Achromobacter species.
49 ccurs in other species, including pathogenic Achromobacter species.
50 C and disk diffusion breakpoints specific to Achromobacter species.
51 er known species that were detected included Achromobacter spp., Afipia spp., Brevundimonas diminuta,
52 as aeruginosa, Stenotrophomonas maltophilia, Achromobacter spp., and Burkholderia spp. decreased by 2
53  sequence analysis was more likely to detect Achromobacter, Stenotrophomonas, and Burkholderia, it wa
54                                              Achromobacter, Stenotrophomonas, and Delftia were predom
55                                              Achromobacter, Stenotrophomonas, and Delftia were preval
56  who were culture positive for Burkholderia, Achromobacter, Stenotrophomonas, and Ralstonia clustered
57 trains, plus three recently genome-sequenced Achromobacter strains, were assigned to 129 sequence typ
58 sent in soil bacteria belonging to the genus Achromobacter Vi antigen assembly follows a widespread g
59 hogen was the most common with pan-resistant Achromobacter xylosoxidans (100%) followed by MDR Stenot
60  MDR Stenotrophomonas maltophilia (46%), MDR Achromobacter xylosoxidans (33%), and finally, pan-resis
61 tant Achromobacter xylosoxidans (n = 9), MDR Achromobacter xylosoxidans (n = 15), pan-resistant Steno
62 ts were divided into 5 groups: pan-resistant Achromobacter xylosoxidans (n = 9), MDR Achromobacter xy
63 nickel resistance loci on plasmid pTOM9 from Achromobacter xylosoxidans 31A, ncc and nre.
64 ntibiotics, there was an increased hazard of Achromobacter xylosoxidans acquisition (HR, 1.24; 95% CI
65 deria cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and atypical mycobacteria are
66                         The CF patients with Achromobacter xylosoxidans and Stenotrophomonas maltophi
67 th MDR pathogens, specifically pan-resistant Achromobacter xylosoxidans and Stenotrophomonas maltophi
68 res before transplantation were reviewed for Achromobacter xylosoxidans and Stenotrophomonas maltophi
69                        Treatment options for Achromobacter xylosoxidans are limited.
70 eruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans but was less sensitive for th
71 o we isolate a novel marine bacterial strain Achromobacter xylosoxidans from the shrimp waste disposa
72                                              Achromobacter xylosoxidans is increasingly recognized as
73                                              Achromobacter xylosoxidans is typically isolated from pu
74                                              Achromobacter xylosoxidans Q19 oxidized PQS congeners wi
75                              This yielded an Achromobacter xylosoxidans strain (Q19) that inactivated
76 dependent on copper (Cu) as a cofactor (e.g. Achromobacter xylosoxidans).
77 tly is comprised of seven species, including Achromobacter xylosoxidans, an opportunistic and nosocom
78 altophilia (n = 26), and CF patients without Achromobacter xylosoxidans, Stenotrophomonas maltophilia
79 plant growth-promoting rhizobacteria such as Achromobacter xylosoxidans, Stentotrophomonas spp., and
80   The most frequently identified species was Achromobacter xylosoxidans, though species-level identif
81 phomonas maltophilia and 2 patients with MDR Achromobacter xylosoxidans.